Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory
We came across a bullish thesis on Atea Pharmaceuticals, Inc. (AVIR) on Substack by Turtles Research. In this article, we will summarize the bulls’ thesis on AVIR. Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals Inc. (AVIR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tang Capital Management Kevin C. Tang | 4,800,000 | $14,352,000 | +1% | 0.79% |
| 2. | Renaissance Technologies Jim Simons | 1,278,400 | $3,822,416 | +6% | 0.01% |
| 3. | Almitas Capital Ron Mass | 715,005 | $2,137,865 | -5% | 0.71% |
| 4. | Newtyn Management Noah Levy And Eugene Dozortsev | 580,000 | $1,734,200 | 0.27% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 533,000 | $1,593,670 | +8% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.36 | 10,000 | $33,614.00 | 476,897 | 2025-01-16 | Filing | |
| $3.19 | 15,000 | $47,884.50 | 466,897 | 2025-01-15 | Filing | |
| $3.36 | 10,000 | $33,614.00 | 476,897 | 2025-01-16 | Filing | |
| $3.19 | 15,000 | $47,884.50 | 466,897 | 2025-01-15 | Filing | |
| $8.57 | 12,000 | $102,795.60 | 23,295 | 2021-12-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.85 | 359,606 | $1,023,474.64 | 451,897 | 2024-12-10 | Filing | |
| $4.00 | 1,841 | $7,367.50 | 5,866,025 | 2024-09-19 | Filing | |
| $4.03 | 22,187 | $89,469.08 | 5,867,866 | 2024-09-18 | Filing | |
| $4.05 | 33,941 | $137,318.50 | 5,890,053 | 2024-09-17 | Filing | |
| $3.49 | 17,544 | $61,144.35 | 65,606 | 2024-06-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,943,065 | $26,739,765 | 0% | |
| 2. | 7,609,812 | $22,753,338 | 18.41% | |
| 3. | 6,018,019 | $17,993,878 | 0% | |
| 4. | 4,727,702 | $14,135,829 | 0% | |
| 5. | 2,485,638 | $7,432,058 | 1.1% |
News See All
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everybody, and welcome to Atea Pharmaceuticals' fourth quarter 2024 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Second Quarter 2024 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Call Transcript May 14, 2024Atea Pharmaceuticals, Inc. misses on earnings expectations.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions].
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Second Quarter 2023 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals' Fourth Quarter and Full Year 2022 Financial Results and Business Update Conference Call.
Billionaire Hedge Funds
